m+Medelevator.RU
← Поиск публикаций
Wiener klinische Wochenschrift · 2020

Relevant parameters for recommendations of physical activity in patients suffering from multiple myeloma : A pilot study.

Название и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Cenik F, Keilani M, Hasenöhrl T, Huber D, Stuhlpfarrer B, Pataraia A, Crevenna R

Аннотация

PURPOSE: This pilot study aimed to describe physical performance, self-reported physical activity, health-related quality of life, anxiety and depression in patients who were assigned from Austrian self-help groups for multiple myeloma patients. These parameters were then discussed in the context of clinical decision-making concerning the recommended type of regular physical activity and exercise.

METHODS: Members of the self-help groups were invited to participate. Physical performance and physical activity were assessed with the 6 min walk test (6MWT), handgrip strength test, timed up and go test (TUG), Tinetti performance oriented mobility assessment (POMA), falls efficacy scale (FES), international physical activity questionnaire (IPAQ), health-related quality of life (EORTC QLQ-C30) and the hospital anxiety and depression scale (HADS).

RESULTS: A total of 40 patients (female:male = 15:25, mean age: 63.8 ± 9.0 years, range 41-80 years) were identified. In total 20 (50%) reached the performance of healthy peers in the tests 6MWT, handgrip strength, TUG and POMA, while 50% showed at least 1 result below the reference value or cut-off-point for each test. Self-reported activity levels were high. Patients showed a tendency to overestimate the risk of falling but a case by case analysis revealed a tendency for underestimating the actual performance in the respective tests (TUG, POMA).

CONCLUSION: The performance of healthy peers was reached by a substantial number of the participants in tests of physical performance and they reported high levels of physical activity. Nevertheless, they tended to overestimate the specific risk of falling. Patients with notably impaired physical performance might be suitable to perform regular physical activity and exercise in an individual therapy, whereas those with good physical performance are suited for training in exercise groups; however, individual contraindications and clinical considerations should be noted in a multiprofessional and interdisciplinary setting.

Перевод полного текста: Перевод в очереди

Читать найденный полный текст

https://creativecommons.org/licenses/by/4.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/ ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Introduction

Multiple myeloma is the second most common hematologic malignancy [ 1 ]. Patients suffering from multiple myeloma show an increase in cancer-specific survival rate due to modern cancer treatment [ 2 , 3 ]. Regular physical activity and exercise are important measures to improve health-related quality of life and physical performance in cancer patients [ 4 – 7 ]. Recommendations for regular physical activity and exercise consist of 150 min/week of moderately intense or 75 min/week of vigorously intense activity or an equivalent combination, muscle strengthening activities of at least moderate intensity at least 2 days/week for each major muscle group and stretching of major muscle groups and tendons [ 2 , 4 – 12 ].

In Austria approximately 2200 patients suffer from multiple myeloma [ 13 ]. There are two main self-help groups in Austria, the so-called Multiples Myelom and Myelom- und Lymphomhilfe offering regular meetings and conferences for patients [ 14 , 15 ]. Nevertheless, the opportunity to be involved in myeloma exercise groups does not yet exist in Austria. Due to bone manifestation of multiple myeloma and special clinical features (especially hypercalcemia and monoclonal gammopathy), a multiprofessional and interdisciplinary approach is required for planning and prescribing regular physical activity and exercise [ 2 , 8 – 12 ]. Hereby, physical performance seems to be an important factor to identify which patients should receive an individual therapy or a therapy in an exercise group [ 11 , 16 – 19 ]. Physical performance depends on endurance capacity, muscle strength and sensorimotor function.

This pilot study aimed to describe physical performance, self-reported physical activity, health-related quality of life, anxiety and depression in patients who were assigned from two Austrian self-help groups. These parameters were then discussed in the context of clinical decision-making, concerning the recommended type of regular physical activity and exercise.

Patients, materials and methods

The two main self-help groups ( Myelom- und Lymphomhilfe and Multiples Myelom ) invited their members with multiple myeloma (aged between 18 and 99 years) to participate in this cross-sectional study. The patients were invited via conferences, emails and the webpage and also via Facebook. After agreeing to participate and checking out the inclusion criteria via telephone, a medical examination was carried out to survey status and demographic data before assessing the parameters presented below. Patients with preliminary stages, such as monoclonal gammopathy of undetermined significance (MGUS) or asymptomatic (smoldering/indolent) myeloma without targeted cancer treatment were excluded from this study. Furthermore, the patients who did not fully understand the study measures or could not perform them, did not speak German sufficiently well or were unable to cognitively or physically follow the course of study were excluded. Illiteracy and refusal to participate were other exclusion criteria. To give the patients from all regions of Austria the best opportunity to participate in this study travel expenses were remunerated.

This pilot study took place at the Department of Physical Medicine, Rehabilitation and Occupational Medicine of the Medical University of Vienna, Austria. The ethics committee of the Medical University of Vienna, Austria approved the present study (EK.-Nr.: 1725/2018). All patients signed a written informed consent before enrolment. The participants were assessed from February 2019 to July 2019.

Assessment

To assess physical performance, the 6‑min walk test (6MWT), the handgrip strength test (HGST by JAMAR® dynamometry [Patterson Medical, Warrenville, IL, USA]), the timed up and go test (TUG) and the Tinetti performance oriented mobility assessment (POMA) were performed. Additionally, the patients were asked to fill in a series of standardized questionnaires and scales: Health-related quality of life of the participants (EORTC QLQ-C30) Clinically significant states of anxiety and depression (hospital anxiety and depression scale, HADS) Self-reported physical activity (international physical activity questionnaire, IPAQ) Fall-related self-efficacy (falls efficacy scale, FES)

The TUG is a commonly used screening tool to assist clinicians to evaluate gait and balance functions, and to identify patients at risk of falling [ 20 ]. There are different procedures for the TUG, namely with normal and fast walking speeds [ 20 ]. In the present study the normal walking speed and cut-off-point for impaired mobility were used (>10 s) based on the recommendations of the Austrian Society for Geriatrics and Gerontology [ 21 ] as well as Podsiadlo and Richardson [ 22 ]. Concerning the POMA, the assessment was based on Tinetti with the following classification: <19 points for high fall risk, 19–23 points for moderate fall risk and 24–28 points for minimal fall risk [ 23 ].

The IPAQ was used to indirectly evaluate an individual’s extent of sedentary behavior and moderate to vigorous physical activity throughout the last 7‑day week. The questionnaire was scored in terms of estimated metabolic equivalent task minutes per week (MET-min/week) [ 24 ]. For the FES the cut-off-points established by Delbaere et al. were used, who classified low concern about falling with 16–19 points, moderate concern with 20–27 points and high concern with 28–64 points [ 25 ]. The HADS evaluation was based on Zigmond and Snaith with the following classification and definition: 0–7 points as normal case, 8–10 as doubtful case, ≥11 as definitive case for each sub-scale [ 26 ]. The age-matched normative data published by Breeman et al. were used for analysis, which were available only for people younger than 65 years old [ 27 ]. Therefore, all older participants were classified as being 65 years old in this study. The 6MWT is widely used as a test of general physical performance, mobility and submaximal exercise capacity [ 28 ]. For the 6MWT, the following formula was used to calculate the predicated walking distance in meters for each participant: (7.57×height cm ) − (5.02×age year ) − (1.76×weight kg ) − 309 for male and (2.11×height cm ) − (2.29×age year ) − (5.78×weight kg ) + 667 for female participants [ 28 ]. For the HGST mean values of each side were used to compare with the JAMAR® age and sex-matched reference values [ 29 – 31 ]. Existing reference values with multiple myeloma patients from the EORTC group were taken from Scott et al. (2008) [ 32 ]. Continuous variables are presented as means and standard deviations, medians and ranges and nominal variables as percentages. The Kolmogorov-Smirnov test was used to test each variable for normal distribution. In case the null-hypothesis from this test was retained, non-parametric solutions like Wilcoxon-signed rank test and Spearman’s correlation were employed to test the related samples for difference in means and correlation, respectively. Due to the retrospective character of the study, no risk ratios could be calculated. Nonetheless, odds ratios (OR, corrected via Haldane-Anscombe for low sample size) were calculated for a pathological test result in one of the primary outcome parameters (columns) given a specific patient characteristic (rows).

Results

In total, 55 patients agreed to participate of whom 9 were excluded due to exclusion criteria (suffering from preliminary stages; had not received any cancer treatment), 4 were not available after self-registration for this study, 1 patient did not want to travel to the study location and 1 patient was recommended not to participate by the family physician. Finally, 40 patients (female:male = 15:25) fulfilled the inclusion criteria. The demographic data of the participants are presented in Table 1 . Table 1 Demographic data n = 40 Mean SD Range Age (years) 63.8 9.0 41–80 Female 64.5 7.7 52–80 Male 63.3 9.8 41–80 Family status n Married 23 Cohabitation 6 Divorced 4 Single 3 Widowed 3 n. s. 1 Employment Yes 7 No (retired) 32 No (housewife) 1 Highest level of education University 13 Business/high school 15 Obligatory education/apprenticeship 12 Household income/year (€) 10,000–25,000 10 25,000–50,000 17 >50,000 3 n. s. 10 Smoker 3 Time since initial diagnosis <1 year 5 1–2 years 5 3–5 years 10 5–10 years 12 >10 years 8 Stem cell transplantation Yes 28 No 12 Pathologic fracture/risk Yes 21 No 19 Radiation due to fracture/risk No 21 Yes 19 Operation due to fracture/risk No 31 Yes 9 Polyneuropathy 22 Cancer rehabilitation performed No 20 Yes 19 n. s. 1 SD standard deviation, n. s. not specified

Table 1
Demographic data
SD standard deviation, n. s. not specified

n = 40MeanSDRange
Age (years)63.89.041–80
Female64.57.752–80
Male63.39.841–80
Family statusn
Married23
Cohabitation6
Divorced4
Single3
Widowed3
n. s.1
Employment
Yes7
No (retired)32
No (housewife)1
Highest level of education
University13
Business/high school15
Obligatory education/apprenticeship12
Household income/year (€)
10,000–25,00010
25,000–50,00017
>50,0003
n. s.10
Smoker3
Time since initial diagnosis
<1 year5
1–2 years5
3–5 years10
5–10 years12
>10 years8
Stem cell transplantation
Yes28
No12
Pathologic fracture/risk
Yes21
No19
Radiation due to fracture/risk
No21
Yes19
Operation due to fracture/risk
No31
Yes9
Polyneuropathy22
Cancer rehabilitation performed
No20
Yes19
n. s.1

Each patient had received ( n = 8) or was still receiving ( n = 32) chemotherapy, new substances and/or immunotherapy (with or without stem cell transplantation). The results of the 6MWT, HGST, POMA, TUG, HADS, IPAQ and EORTC QLQ-C30 are presented in Table 2 . Table 2 Results of all parameters Parameter Total ( n = 40) mean ± SD Median Range 6‑MWT in m 548 ± 128 573 225–835 HGST in kg 32.4 ± 9.6 32.5 17–51 POMA (<19 = high fall risk) (points) 23.5 ± 4.8 26 12–28 Balance 13.4 ± 3.0 15 5–16 Gait 10.1 ± 2.1 11 6–12 TUG (s) 9.5 ± 3.1 9 5.5–21.0 FES 21.2 ± 6.0 20 16–39 HADS (points) 10.5 ± 5.0 10 1–23 Anxiety 5.7 ± 3.2 6 0–12 Depression 4.9 ± 2.7 4 1–11 MET-min/week Total ( n = 35) mean ± SD Vigorous 888.0 ± 1873.3 0 0–10,080 Moderate 830 ± 1275.3 240 0–5040 Walk 1110.7 ± 1127.8 792 0–2772 Total 2829.5 ± 3041.5 1584 0–16,506 EORTC QLQ-C30 (points) Total ( n = 40) mean ± SD Reference Global health status/QOL 60.0 ± 21.5 62.5 55.7 ± 22.8 Physical functioning 75.3 ± 18.1 80.0 67.7 ± 23.4 Role functioning 65.0 ± 23.5 66.7 60.1 ± 33.4 Emotional functioning 67.3 ± 24.7 66.7 71.3 ± 22.7 Cognitive functioning 70.8 ± 24.7 66.7 78.1 ± 23.8 Social functioning 64.6 ± 29.0 66.7 63.2 ± 31.0 Fatigue 47.8 ± 22.3 44.4 48.7 ± 26.7 Nausea and vomiting 7.1 ± 13.5 0 10.5 ± 19.2 Pain 36.7 ± 30.5 33.3 47.1 ± 33.9 Dyspnea 30.0 ± 25.9 33.3 26.0 ± 27.3 Insomnia 42.5 ± 33.7 33.3 28.9 ± 30.6 Appetite loss 12.5 ± 24.7 0 23.2 ± 30.2 Constipation 13.3 ± 27.0 0 23.2 ± 29.9 Diarrhea 20.0 ± 30.0 0 9.6 ± 19.4 Financial difficulties 20.0 ± 29.0 0 16.1 ± 26.6 SD standard deviation, QOL quality of life, 6MWT 6-min walk test, HGST handgrip strength test, POMA Tinetti performance oriented mobility assessment, TUG timed up and go test, FES falls efficacy scale, HADS hospital anxiety and depression scale, MET metabolic equivalent of task, EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30

Table 2
Results of all parameters
SD standard deviation, QOL quality of life, 6MWT 6-min walk test, HGST handgrip strength test, POMA Tinetti performance oriented mobility assessment, TUG timed up and go test, FES falls efficacy scale, HADS hospital anxiety and depression scale, MET metabolic equivalent of task, EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30

ParameterTotal ( n = 40) mean ± SDMedianRange
6‑MWT in m548 ± 128573225–835
HGST in kg32.4 ± 9.632.517–51
POMA (<19 = high fall risk) (points)23.5 ± 4.82612–28
Balance13.4 ± 3.0155–16
Gait10.1 ± 2.1116–12
TUG (s)9.5 ± 3.195.5–21.0
FES21.2 ± 6.02016–39
HADS (points)10.5 ± 5.0101–23
Anxiety5.7 ± 3.260–12
Depression4.9 ± 2.741–11
MET-min/weekTotal ( n = 35) mean ± SD
Vigorous888.0 ± 1873.300–10,080
Moderate830 ± 1275.32400–5040
Walk1110.7 ± 1127.87920–2772
Total2829.5 ± 3041.515840–16,506
EORTC QLQ-C30 (points)Total ( n = 40) mean ± SDReference
Global health status/QOL60.0 ± 21.562.555.7 ± 22.8
Physical functioning75.3 ± 18.180.067.7 ± 23.4
Role functioning65.0 ± 23.566.760.1 ± 33.4
Emotional functioning67.3 ± 24.766.771.3 ± 22.7
Cognitive functioning70.8 ± 24.766.778.1 ± 23.8
Social functioning64.6 ± 29.066.763.2 ± 31.0
Fatigue47.8 ± 22.344.448.7 ± 26.7
Nausea and vomiting7.1 ± 13.5010.5 ± 19.2
Pain36.7 ± 30.533.347.1 ± 33.9
Dyspnea30.0 ± 25.933.326.0 ± 27.3
Insomnia42.5 ± 33.733.328.9 ± 30.6
Appetite loss12.5 ± 24.7023.2 ± 30.2
Constipation13.3 ± 27.0023.2 ± 29.9
Diarrhea20.0 ± 30.009.6 ± 19.4
Financial difficulties20.0 ± 29.0016.1 ± 26.6

On average the participants showed a moderate subjective risk of falling (moderate concern in the FES) and a low to moderate fall risk in the objective fall risk assessments (POMA and TUG test, Table 3 ). In more detail, 20 patients (50%) reported a moderate or high concern about falling (FES >10) while in fact only 10 patients (25%) showed an elevated risk in the TUG test, of whom 9 patients (22.5%) were deemed at high risk by the POMA. Among those patients who reported a moderate to high subjective risk of falling (in the FES), 70% performed well in the remaining objective risk assessment tools. A case by case analysis therefore revealed a tendency of patients to overestimate the fall risk and underestimate the actual performance in the respective tests. Table 3 Patients underwent four different objective measures of physical performance (6MWT, POMA, TUG, HGST) Sex Age (years) 6MWT (m) HGST (kg) POMA (points) TUG (s) m 59 600 38 28 8 m 54 643 44 28 7 m 61 640 41 27 7 f 67 530 26 25 9 m 70 550 38 27 8 m 65 750 42 28 6 f 64 475 26 27 9 f 59 560 26 27 9 f 63 580 34 28 9 m 67 602 51 28 8 f 52 625 30 27 8 f 66 605 22 26 8 f 66 517 32 26 7 m 51 720 45 27 9 m 60 605 43 26 9 m 55 835 40 26 8 m 70 620 30 26 7 m 57 660 50 28 9 m 70 680 34 27 6 f 61 575 26 28 7 m 69 470 36 26 7 m 59 600 50 20 8 f 66 460 22 22 8 m 79 500 26 16 9 m 61 500 32 25 10 f 62 590 15 24 9 m 53 650 40 27 8 f 57 570 26 24 13 f 71 478 18 21 9 m 78 525 30 18 10 m 55 660 20 25 13 m 72 520 35 18 11 m 41 650 36 21 9 m 59 358 30 22 12 f 78 360 20 16 14 f 55 305 17 15 12 m 61 425 38 13 11 m 80 427 50 18 11 m 77 225 37 12 21 f 80 270 18 15 19 N = 20 patients showed a pathological result in at least one test ( bold ) while the other 20 patients reached the individual cut-off-points of the healthy peers ( italic ) m male, f female, 6MWT 6-min walk test in meters, POMA Tinetti performance oriented mobility assessment, TUG timed up and go test, HGST handgrip strength test of the dominant hand in kilograms

Table 3
Patients underwent four different objective measures of physical performance (6MWT, POMA, TUG, HGST)
N = 20 patients showed a pathological result in at least one test ( bold ) while the other 20 patients reached the individual cut-off-points of the healthy peers ( italic ) m male, f female, 6MWT 6-min walk test in meters, POMA Tinetti performance oriented mobility assessment, TUG timed up and go test, HGST handgrip strength test of the dominant hand in kilograms

SexAge (years)6MWT (m)HGST (kg)POMA (points)TUG (s)
m5960038288
m5464344287
m6164041277
f6753026259
m7055038278
m6575042286
f6447526279
f5956026279
f6358034289
m6760251288
f5262530278
f6660522268
f6651732267
m5172045279
m6060543269
m5583540268
m7062030267
m5766050289
m7068034276
f6157526287
m6947036267
m5960050208
f6646022228
m7950026169
m61500322510
f6259015249
m5365040278
f57570262413
f7147818219
m78525301810
m55660202513
m72520351811
m4165036219
m59358302212
f78360201614
f55305171512
m61425381311
m80427501811
m77225371221
f80270181519

The third objective test for physical performance was the handgrip strength test. Overall, 6 (15%) participants showed a reduced handgrip strength in comparison with age and sex-matched reference values. The 6MWT was employed as fourth objective evaluation of physical performance and 12 patients showed results below the individual age, sex, height and weight-predicted values (see methods). Results from this test are the only data in this study that followed a normal distribution (Kolmogorov-Smirnov test retains the null hypothesis of normal distribution at p > 0.20). Patients walked on average 547.9 m in 6 min and the standard deviation was 127.8 m. Patients who did not reach the predicted value ( n = 12) walked on average 419 m and those who did reach the predicted values ( n = 28) 603 m. Despite the low sample size, both groups followed a normal distribution (Kolmogorov-Smirnov test p > 0.20) and the means in these two groups are highly significantly different (2-sided Wilcoxon-signed-rank test p < 0.01). On average, patients who reached the predicted values walked 43% further in 6 min than the peers who did not reach their predicted values. When combining the objective tests for hand grip strength, exercise capacity (6MWT) and risk of falling (TUG test and POMA), 20 (50%) patients in the sample of 40 multiple myeloma patients showed a pathologic result in at least 1 test, while the other 50% performed above the cut-off points in all tests (Table 3 ).

Self-reported physical activity measured by the IPAQ showed high activity levels among the patients in this study. During the scoring procedure, 5 participants were excluded from the analysis (due to either missing information regarding duration of physical activity or being an outlier: self-reported total activity >960 min). In total, 8 patients (23%) showed total MET-min values equivalent of low activity, while 77% reported at least moderate activity levels. In terms of exercise intensity, 8 patients reported only walking activity during the last week. The remaining patients performed at least moderate if not vigorous activity. The 12 participants who showed results below the individual age, sex, height and weight-predicted values in the 6MWT also seemed to have impairments in mobility, self-reported physical activity and health-related quality of life. Furthermore, they had higher levels regarding depression and anxiety (Table 4 ). With respect to the small sample size of n = 40, no further statistical evaluation was performed. Table 4 Comparison of the patients below ( n = 12) the individual age, sex, height and weight-predicted values, with the remaining patients 6MWT (m) Age POMA (points) TUG (s) HGST (kg) HADS (points) FES (points) MET-min/week QOL (points) Pain (points) Patients below their reference values (n = 12) Mean 419.8 65.8 19.0 12.2 29.8 11.4 25.6 2902.7 57.6 37.5 SD 123.9 12.1 4.8 4.1 10.3 4.9 8.4 2513.1 25.5 29.4 Median 426.0 65.0 19.5 11.5 31 13.0 22.5 1413.0 58.3 33.3 Remaining patients (n = 28) Mean 602.8 62.9 25.4 8.3 34.1 10.1 19.3 2791.4 61.0 36.3 SD 83.2 7.3 3.4 1.5 9.7 5.1 3.3 3336.9 20.0 31.4 Median 601.0 62.5 27.0 8.2 34.0 10.0 18.0 1653.0 66.7 33.3 SD standard deviation, m male, f female, 6MWT 6-min walk test, POMA Tinetti performance oriented mobility assessment, TUG timed up and go test, HGST handgrip strength test of the dominant hand, HADS hospital anxiety and depression scale, FES falls efficacy scale, MET metabolic equivalent of task, QOL quality of life

Table 4
Comparison of the patients below ( n = 12) the individual age, sex, height and weight-predicted values, with the remaining patients
SD standard deviation, m male, f female, 6MWT 6-min walk test, POMA Tinetti performance oriented mobility assessment, TUG timed up and go test, HGST handgrip strength test of the dominant hand, HADS hospital anxiety and depression scale, FES falls efficacy scale, MET metabolic equivalent of task, QOL quality of life

6MWT (m)AgePOMA (points)TUG (s)HGST (kg)HADS (points)FES (points)MET-min/weekQOL (points)Pain (points)
Patients below their reference values (n = 12)
Mean419.865.819.012.229.811.425.62902.757.637.5
SD123.912.14.84.110.34.98.42513.125.529.4
Median426.065.019.511.53113.022.51413.058.333.3
Remaining patients (n = 28)
Mean602.862.925.48.334.110.119.32791.461.036.3
SD83.27.33.41.59.75.13.33336.920.031.4
Median601.062.527.08.234.010.018.01653.066.733.3

The ORs are presented in Table 5 . All ORs showed only very weak evidence of impacting any of the outcomes (OR of 1 contained in the 95% confidence interval). In terms of effect size, an approximation of Cohen’s d was calculated from the OR (Table 6 ). Among all recorded disease-modifying factors, only stem cell therapy in addition to chemotherapy showed a strong effect on three of the four primary outcome parameters (reducing the odds of a pathological outcome). Oddly, the positive patient characteristics had a positive effect size on not reaching the cut-off in the primary outcomes. Table 5 Odds ratios for pathologic test results TUG (s) POMA (points) 6MWT (m) HGST (kg) Rehabilitation 1.07 (0.26; 4.10) 1.48 (0.28; 4.93) 0.73 (0.23; 3.27) 2.26 (0.26; 7.68) Stem cell therapy 0.10 (0.05; 2.54) 0.17 (0.02; 8.98) 0.11 (0.02; 7.43) 1.19 (0.14; 7.96) PNP 1.55 (0.30; 4.78) 1.01 (0.24; 4.19) 1.18 (0.24; 3.47) 1.61 (0.23; 6.61) Smoking 1.57 (0.14; 10.4) 0.43 (0.03; 14.6) 4.37 (0.22; 16.2) 12.4 (0.31; 28.3) TUG timed up and go test, POMA performance oriented mobility assessment, 6MWT 6-min walk test, HGST handgrip strength test, PNP polyneuropathy Table 6 Effect size on failing an outcome parameter cut-off TUG (s) POMA (points) 6MWT (m) HGST (kg) Rehabilitation −0.02 0.09 −0.07 0.20 Stem cell therapy −0.57 −0.42 −0.52 0.04 PNP 0.17 0.00 0.04 0.11 Smoking 0.13 −0.20 0.35 0.60 TUG Timed up and Go test, POMA Performance Oriented Mobility Assessment, 6MWT 6-minute walk test, HGST Handgrip strength test, PNP Polyneuropathy

Table 5
Odds ratios for pathologic test results
TUG timed up and go test, POMA performance oriented mobility assessment, 6MWT 6-min walk test, HGST handgrip strength test, PNP polyneuropathy

TUG (s)POMA (points)6MWT (m)HGST (kg)
Rehabilitation1.07 (0.26; 4.10)1.48 (0.28; 4.93)0.73 (0.23; 3.27)2.26 (0.26; 7.68)
Stem cell therapy0.10 (0.05; 2.54)0.17 (0.02; 8.98)0.11 (0.02; 7.43)1.19 (0.14; 7.96)
PNP1.55 (0.30; 4.78)1.01 (0.24; 4.19)1.18 (0.24; 3.47)1.61 (0.23; 6.61)
Smoking1.57 (0.14; 10.4)0.43 (0.03; 14.6)4.37 (0.22; 16.2)12.4 (0.31; 28.3)

Table 6
Effect size on failing an outcome parameter cut-off
TUG Timed up and Go test, POMA Performance Oriented Mobility Assessment, 6MWT 6-minute walk test, HGST Handgrip strength test, PNP Polyneuropathy

TUG (s)POMA (points)6MWT (m)HGST (kg)
Rehabilitation−0.020.09−0.070.20
Stem cell therapy−0.57−0.42−0.520.04
PNP0.170.000.040.11
Smoking0.13−0.200.350.60

Discussion

The present study was performed by analyzing members of two self-help groups in Austria. Self-help groups are an essential measure of patient involvement and play an important part in the healthcare system. Members of self-help groups are often well-informed about the management of the disease and highly motivated to participate in regular physical activity. The finding that most patients reported at least moderate to high levels of physical activity supports this observation. Moreover, a substantial amount of study participants reached the performance of the healthy peers in tests of physical performance, such as the 6MWT ( n = 28, 70%), the TUG test ( n = 29, 73%), the POMA ( n = 26, 65%) and handgrip strength test ( n = 34, 85%). While this performance seems to be underestimated by the patients themselves, they tend to overestimate theispecific risk of falling (FES). This discrepancy is of particular interest as a higher subjective concern of falling can lead in the long run to a vicious circle between impaired physical performance and physical activity. This consequently leads to loss of muscle and bone mass lowering bone density and therefore increasing risk of bone fractures. This is in line with the results as the 12 participants with results in the 6MWT below the individual age, sex, height and weight-predicted values had lower self-reported physical activity and health-related quality of life as well as higher levels of depression and anxiety. Patients with impaired subjective and objective walking performance should therefore be encouraged to at least maintain physical activity levels for as long as possible and perform suitable and supervised individual exercise to improve sensorimotor function, mobility, muscle strength, endurance capacity and independence from others’ help. In comparison, exercise studies with multiple myeloma patients usually exclude patients with pathological fractures or increased risk of fractures [ 11 , 16 , 17 ]. Therefore, a multidisciplinary and interdisciplinary approach as described is necessary to manage the actual condition and to evaluate bone load-bearing capacity of this patient group [ 11 , 18 , 19 ].

Most patients (75%) who did not reach normal values in the 6MWT, TUG, POMA or handgrip strength tests did not reach their goal in at least two of these tests. Data only allow a differentiation between patients who reached the reference values and those who did not. More than half ( n = 22, 55%) of the patients reported having symptoms of polyneuropathy, which could influence the fear of falling and fall risk in theory; however, the performance in the four objective physical performance tests (6MWT, TUG, POMA, HGST) did not seem to differ between patients with PNP and those without. Overall 20 (50%) patients in the sample of 40 multiple myeloma patients did not reach the reference values in at least 1 of the tests for handgrip strength, exercise capacity (6MWT) and risk of falling (TUG test and POMA), while the other 50% performed above cut-off values in all tests (Table 3 ). Clinical recommendations for group therapy could safely be given to the latter patient sample, while the former group would be assigned to single therapy sessions. Additionally, a patient’s medical history, clinical examination, laboratory parameters, electrocardiography, echocardiography, exercise testing, spirometry, and radiographic findings are required for planning and prescribing regular physical activity and exercise for patients suffering from multiple myeloma in an interdisciplinary setting [ 11 , 18 , 19 ]. Special clinical features that clinicians have to consider are bone manifestation, hypercalcemia (with risk of cardiac arrhythmia or kidney failure) and monoclonal gammopathy [ 11 , 18 , 19 ]. Additionally, due to the natural history of multiple myeloma with changing clinical status over time, exercise should be performed under supervision of physicians. Besides these objective measures there are also subjective measures, such as pain which was assessed in this study via EORTC QLQ-C30; however, even the patients in the non-fit group (6MWT values below the individual predicted values) reported pain intensity similar to the reference values. Moreover, besides radiographic findings pain is an important factor for evaluation of spinal stability of cancer lesions [ 33 ] and pathological fractures [ 34 , 35 ]. As pain will always be a limiting factor for physical activity and exercise, the symptom pain should be considered when planning exercise groups and treated in a multidisciplinary manner by use of a multimodal approach [ 19 ].

None of the recorded patient characteristics (oncological rehabilitation, additional stem cell therapy, polyneuropathy, and smoking) could establish statistical evidence of modifying the outcome of the primary parameters (POMA, TUG, 6MWT, HGST). Stem cell therapy, however, showed a strong effect size on the balance tests and walking distance. A future study on multiple myeloma patients should therefore bolster this finding with greater sample size. Moreover, more confounding variables from the patient’s medical records, such as bone metastases, fractures, precise chemotherapy regimen and a more detailed history of physical therapy should be taken into account.

The present study has some limitations. The majority of the mobility tests were developed for use in geriatric patients in the original context. For the POMA and TUG there are various existing cut-off points, classifications and approaches for the test procedure in the literature but mostly researched in older people [ 20 ]. Moreover, due to non-existing reference groups in patients older than 65 years, the oldest participants were classified as if they were 65 years old. Despite the low sample size of n = 40 patients, statistical inference was possible to a certain degree; however, a larger sample would have been beneficial and would have allowed a stronger generalizability. When comparing subgroups, however, statistical analysis is less reliable and warrants great caution. Another weakness of the assessment battery was its length, which might have discouraged some participants from participating in this study in the first place. Finally, the recruitment of this study sample was performed via invitations. Therefore, a selection bias regarding motivation to participate is to be expected. Clinical experience shows that self-help group members are especially motivated, educated and active, which is a clear bias towards a generally healthier patient sample. Moreover, assessing fracture risk from the existing patients’ diagnostics, which were incomplete in this respect and not including radiographic assessments during the study protocol made it impossible to categorize the participants into high, moderate, and low fracture risk as a possible basis for more precise recommendations for regular physical activity and exercise in patients with multiple myeloma.

Conclusion

A substantial number of participants reached the performance of healthy peers in tests of physical performance and reported high levels of physical activity. Nevertheless, they tended to overestimate the specific risk of falling. Patients with notably impaired physical performance might be suitable to perform regular physical activity and exercise in an individual therapy, whereas those with good physical performance are suited for training in exercise groups. To ensure safety and effectiveness of these interventions in patients with multiple myeloma, however, individual contraindications and clinical considerations should be noted in a multiprofessional and interdisciplinary setting.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Funding

Open access funding provided by Medical University of Vienna.

Conflict of interest

F. Cenik, M. Keilani, T. Hasenöhrl, D. Huber, B. Stuhlpfarrer, A. Pataraia, and R. Crevenna declare that they have no competing interests.

References

1. Radocha J Hájek R Brožová L Simplified novel prognostic score for real-life older adults with multiple myeloma-registry-based analysis Ann Hematol 2019 98 4 951 962 10.1007/s00277-018-3568-2 30539278

2. Warren JL Harlan LC Stevens J Little RF Abel GA Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States J Clin Oncol 2013 31 1984 1989 10.1200/JCO.2012.46.3323 23569317 PMC3661935

3. Kumar SK Dispenzieri A Lacy MQ Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients Leukemia 2014 28 1122 1128 10.1038/leu.2013.313 24157580 PMC4000285

4. Mock V Pickett M Ropka M Fatigue and quality of life outcome of exercise during cancer treatment Cancer Pract 2001 9 3 119 127 10.1046/j.1523-5394.2001.009003119.x 11879296

5. Crevenna R Aspects of cancer rehabilitation: an Austrian perspective Disabil Rehabil 2019 27 1 10.1080/09638288.2018.1522554 30686037

6. Crevenna R Cancer rehabilitation and palliative care-two important parts of comprehensive cancer care Support Care Cancer 2015 23 12 3407 3408 10.1007/s00520-015-2977-1 26441078

7. Palma S Keilani M Hasenoehrl T Crevenna R Impact of supportive therapy modalities on heart rate variability in cancer patients—a systematic review Disabil Rehabil 2018 4 1 8 10.1080/09638288.2018.1514664 30512975

8. American College of Sports Medicine Schmitz KH Courneya KS Matthews C American College of Sports Medicine roundtable on exercise guidelines for cancer survivors Med Sci Sports Exerc 2010 42 7 1409 1426 10.1249/MSS.0b013e3181e0c112 20559064

9. Dimeo F Schwartz S Fietz T Wanjura T Boning D Thiel E Effects of endurance training on the physical performance of patients with hematological malignancies during chemotherapy Support Care Cancer 2003 11 623 628 10.1007/s00520-003-0512-2 12942360

10. Cha S Kim I Lee SU Seo KS Effect of an inpatient rehabilitation program for recovery of deconditioning in hematologic cancer patients after chemotherapy Ann Rehabil Med 2018 42 6 838 845 10.5535/arm.2018.42.6.838 30613077 PMC6325318

11. Keilani M Kainberger F Pataraia A Typical aspects in the rehabilitation of cancer patients suffering from metastatic bone disease or multiple myeloma Wien Klin Wochenschr 2019 10.1007/s00508-019-1524-3 31267163 PMC6851044

12. Kumar SK Rajkumar V Kyle RA Multiple myeloma Nat Rev Dis Primers 2017 3 17046 10.1038/nrdp.2017.46 28726797

13. Statistik Austria Plasmozytom, myelom 2019

14. Multiples Myelom. 2019. http://www.multiplesmyelom.at . Accessed 7th Aug 2019

15. Myelom-Lymphom. 2019. http://www.myelom-lymphom.at . Accessed 7th Aug 2019

16. Coleman EA Coon S Hall-Barrow J Richards K Gaylor D Stewart B Feasibility of exercise during treatment for multiple myeloma Cancer Nurs 2003 26 5 410 419 10.1097/00002820-200310000-00012 14710804

17. Groeneveldt L Mein G Garrod R A mixed exercise training programme is feasible and safe and may improve quality of life and muscle strength in multiple myeloma survivors BMC Cancer 2013 13 31 10.1186/1471-2407-13-31 23347597 PMC3584898

18. Crevenna R Kainberger F Wiltschke C Cancer rehabilitation: current trends and practices within an Austrian university hospital center Disabil Rehabil 2018 10.1080/09638288.2018.1514665 30328719

19. Crevenna R From neuromuscular electrical stimulation and biofeedback-assisted exercise up to triathlon competitions-regular physical activity for cancer patients in Austria Eur Rev Aging Phys Act 2013 10 53 55 10.1007/s11556-012-0110-8

20. Schädler S Grenzwerte (Cut-off), Sensitivität und Spezifität 2010

21. Österreichische Gesellschaft für Geriatrie und Gerontologie Geriatrisches Basisassessment 2019

22. Podsiadlo D Richardson S The timed “Up & Go”: a test of basic functional mobility for frail elderly persons J Am Geriatr Soc 1991 39 2 142 148 10.1111/j.1532-5415.1991.tb01616.x 1991946

23. Tinetti ME Performance-oriented assessment of mobility problems in elderly patients J Am Geriatr Soc 1986 34 2 119 126 10.1111/j.1532-5415.1986.tb05480.x 3944402

24. Craig CL Marshall AL Sjöström M International physical activity questionnaire: 12-country reliability and validity Med Sci Sports Exerc 2003 35 8 1381 1395 10.1249/01.MSS.0000078924.61453.FB 12900694

25. Delbaere K Close JC Mikolaizak AS Sachdev PS Brodaty H Lord SR The Falls Efficacy Scale International (FES-I). A comprehensive longitudinal validation study Age Ageing 2010 39 2 210 216 10.1093/ageing/afp225 20061508

26. Zigmond AS Snaith RP The hospital anxiety and depression scale Acta Psychiatr Scand 1983 67 6 361 370 10.1111/j.1600-0447.1983.tb09716.x 6880820

27. Breeman S Cotton S Fielding S Jones GT Normative data for the Hospital Anxiety and Depression Scale Qual Life Res 2015 24 2 391 398 10.1007/s11136-014-0763-z 25064207

28. Enright PL Sherrill DL Reference equations for the six-minute walk in healthy adults Am J Respir Crit Care Med 1998 158 5 Pt 1 1384 1387 10.1164/ajrccm.158.5.9710086 9817683

29. Mathiowetz V Weber K Volland G Kashman N Reliability and validity of grip and pinch strength evaluations J Hand Surg Am 1984 9 2 222 226 10.1016/S0363-5023(84)80146-X 6715829

30. Mathiowetz V Kashman N Volland G Weber K Dowe M Rogers S Grip and pinch strength: normative data for adults Arch Phys Med Rehabil 1985 66 2 69 74 3970660

31. Mathiowetz V Wiemer DM Federman SM Grip and pinch strength: norms for 6- to 19-years-old Am J Occup Ther 1986 40 10 705 711 10.5014/ajot.40.10.705 3777107

32. Scott NW Fayers PM Neil KA EORTC QLQ-C30 Reference Values. EORTC Quality of Life Group 2008

33. Mirels H Metastatic disease in long bones: a proposed scoring system for diagnosing impending pathologic fractures Clin Orthop Relat Res 2003 415 Suppl S4 S13 10.1097/01.blo.0000093045.56370.dd 14600587

34. Macedo F Ladeira K Pinho F Bone metastases: an overview Oncol Rev 2017 11 1 321 10.4081/oncol.2017.321 28584570 PMC5444408

35. Knips L Bergenthal N Streckmann F Monsef I Elter T Skoetz N Aerobic physical exercise for adult patients with haematological malignancies Cochrane Database Syst Rev 2019 10.1002/14651858.CD009075.pub3 30702150 PMC6354325

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты